T Cell News and Research

Latest T Cell News and Research

Point Loma Nazarene University accepts applications for Kyoto Prize Journalism Fellowship

Point Loma Nazarene University is now accepting applications for its Kyoto Prize Journalism Fellowship, a unique learning opportunity for a journalist who has worked to attain a level of excellence in his or her field and hopes to further integrity in the sciences and arts. The selected journalist will attend the 26th annual Kyoto Prize presentation ceremony and will interact with the latest Kyoto Prize laureates in Kyoto, Japan, November 7-14, 2010.

18 Aug 2010

Regenicin acquires worldwide exclusive license to know-how technology

Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").

18 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

XOMA sells royalty interest in CIMZIA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA® (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is covered by a license to XOMA's Bacterial Cell Expression technology.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Toshiba America Medical Systems/RSNA issues grant to three researchers

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.

18 Aug 2010

Xcelligence System provides real-time detection of neuronal cell death

Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.

18 Aug 2010

Research shows mutation in Prox1 gene may lead to memory, learning problems

St. Jude Children's Research Hospital investigators showed a gene named Prox1 is a key player in normal development of a brain structure crucial for learning and memory and remains active throughout life, nurturing the cells vital for making new memories.This study focused on a small region of the hippocampus known as the dentate gyrus, a brain structure needed for memory and learning that is home to the subgranular zone where the neural stem cells destined to become granule cells are housed. The dentate gyrus is one of two regions of the adult brain where neural stem cells continue to produce the precursor cells that ultimately differentiate into neurons.

18 Aug 2010

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.

18 Aug 2010

Mature stem cell research development hinges on quality of science peer review

Are there too many stem cell research journals? This question has been posed by Drs. Paul Sanberg and Cesar Borlongan of the Department of Neurosurgery and Brain Repair at the University of South Florida. Their article appears in the current issue of Stem Cell Reviews and Reports.Both Sanberg and Borlongan are concerned about the quality of the science being published in the proliferating stem cell journals.

18 Aug 2010

Researcher unveils unique stem cell partnership that can lead to advances in regenerative medicine

A study led by a researcher at Albert Einstein College of Medicine of Yeshiva University has revealed a unique "partnership" between two types of bone marrow stem cells, which could lead to advances in regenerative medicine. The aim of regenerative medicine is to enable the body to repair, replace, restore or regenerate damaged or diseased cells, tissues and organs.

18 Aug 2010

UK scientists receive Royal Society awards for cancer research

Two Cancer Research UK scientists were recently awarded prestigious Royal Society Awards, while a number of Cancer Research UK scientists were elected fellows of the Royal Society and the Academy of Medical Sciences.Dr Tomas Lindahl is the recipient of the Royal Society Copley Medal, the world's oldest prize for scientific achievement, and Professor Stephen West is awarded this year's GlaxoSmithKline Prize and Lecture.

18 Aug 2010

Researchers develop genetically mutated stem cells for myelin research

Vanishing White Matter (VWM) disease is a devastating condition that involves the destruction of brain myelin due to a mutation in a central factor. To understand the disease and test potential treatments that could apply to other disorders, such as multiple sclerosis, Prof. Orna Elroy-Stein of Tel Aviv University's Department of Cell Research and Immunology is leading a scientific breakthrough by developing laboratory mice which carry the VWM mutation an important new tool.

18 Aug 2010

Life Technologies, CEVEC Pharmaceuticals sign licensing agreement to supply CAP-T expression kits

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation, a leading provider of innovative life science solutions based in Carlsbad, California. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC's proprietary CAP-T cells to the global life science research community.

18 Aug 2010

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

18 Aug 2010

Researchers discover sugars that fight body's natural defenses, vaccines

A special set of sugars found on some disease-causing pathogens helps those pathogens fight the body's natural defenses as well as vaccines, say two Iowa State University researchers.This discovery may be a first step in understanding a disease family that includes tuberculosis for which there are currently no good vaccines or cures.Nicola Pohl, professor of chemistry, and Christine Petersen, assistant professor of veterinary pathology, discovered that a natural coating of sugar interacts with the body's defense cells to dampen its own immune response.

18 Aug 2010

Adult stem cells associated with poor prognosis of cancer: Research

Adult stem cells that are vital for airway repair in the lung but that persist in areas where pre-cancerous lesions are found are associated with a poor prognosis in patients who develop cancer, even those with early stage disease, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.These adult stem cells are found in repairing areas after injury and also are found in pre-cancerous areas, suggesting that these cells may mutate and become cancer causing stem cells, making them a potential cell-of-origin for lung cancer and a possible target for prevention strategies and new targeted therapies.

18 Aug 2010

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation, today announced a research and development collaboration agreement with Monash University in Australia. The partnership will allow scientists from the University's Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell's proprietary C'elle menstrual stem cell technology (MenScs) to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis.

18 Aug 2010

CaridianBCT releases version 6.0 of Trima Accel Automated Blood Collection System

CaridianBCT, the leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, announced the global release of the Trima Accel® Automated Blood Collection System Version 6.0. The latest version of the flagship automated blood collection platform provides streamlined operations and potentially increased cost savings for customers worldwide.

18 Aug 2010

Aastrom Bioscience fourth quarter net loss decreases to $0.18 per share

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported operating results for the fourth quarter and fiscal year ended June 30, 2010.

18 Aug 2010

T Cell News and Research

Latest T Cell News and Research

Point Loma Nazarene University accepts applications for Kyoto Prize Journalism Fellowship

Regenicin acquires worldwide exclusive license to know-how technology

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

XOMA sells royalty interest in CIMZIA

FDA grants orphan drug designation to NephRx's lead product NX001

Toshiba America Medical Systems/RSNA issues grant to three researchers

Xcelligence System provides real-time detection of neuronal cell death

Research shows mutation in Prox1 gene may lead to memory, learning problems

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Mature stem cell research development hinges on quality of science peer review

Researcher unveils unique stem cell partnership that can lead to advances in regenerative medicine

UK scientists receive Royal Society awards for cancer research

Researchers develop genetically mutated stem cells for myelin research

Life Technologies, CEVEC Pharmaceuticals sign licensing agreement to supply CAP-T expression kits

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

Researchers discover sugars that fight body's natural defenses, vaccines

Adult stem cells associated with poor prognosis of cancer: Research

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

CaridianBCT releases version 6.0 of Trima Accel Automated Blood Collection System

Aastrom Bioscience fourth quarter net loss decreases to $0.18 per share

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in